Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. announced a change in the business scope of its wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd., which has completed the registration procedures and obtained a new business license [1] Group 1: Company Information - The new business license includes the following basic registration information: Unified Social Credit Code: 913418007316537262, Name: Fuyuan Pharmaceutical Co., Ltd., Type: Limited Liability Company (wholly owned by a legal entity), Legal Representative: Huang He, Registered Capital: 75 million yuan, Establishment Date: September 3, 2001, Address: Economic and Technological Development Zone, Xuancheng City, Anhui Province [1] Group 2: Business Scope - The business scope after the change includes: - Licensed projects: Drug production, entrusted drug production, drug import and export, disinfectant production (excluding hazardous chemicals), health food production, cosmetics production, drug internet information services, and electricity supply business [1] - General projects: Daily chemical product manufacturing, daily chemical product sales, wholesale and retail of cosmetics, internet sales (excluding goods requiring permits), technical services, development, consulting, exchange, transfer, promotion, medical packaging materials manufacturing, plastic products manufacturing, technology import and export, goods import and export, and domestic trade agency (excluding licensed businesses) [1]

证券代码：601089 证券简称：福元医药 公告编号：临 2025-056 北京福元医药股份有限公司 关于全资子公司营业执照变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 北京福元医药股份有限公司(以下简称"公司") 的全资子公司福 元药业有限公司于近日对经营范围进行了变更，并完成了工商变更登 记手续，取得了宣城市市场监督管理局换发的《营业执照》。变更后 《营业执照》基本登记信息如下： 名称：福元药业有限公司 类型：有限责任公司（非自然人投资或控股的法人独资） 法定代表人：黄河 注册资本：柒仟伍佰万圆整 成立日期：2001 年 09 月 03 日 住所：安徽省宣城市经济技术开发区 统一社会信用代码：913418007316537262 经营范围：许可项目：药品生产；药品委托生产；药品进出口； 消毒剂生产（不含危险化学品）；保健食品生产；化妆品生产；药品 互联网信息服务；供电业务（依法须经批准的项目，经相关部门批准 后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件 为准）一般项目：日用化学产品制造；日用 ...

Core Viewpoint - Fuyuan Pharmaceutical's subsidiary, Fuyuan Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the "Salicylic Acid Phenol Plaster," transferring the marketing authorization from Xi'an Kanghua Pharmaceutical Co., Ltd. to Fuyuan Pharmaceutical Co., Ltd. [1] Group 1 - Fuyuan Pharmaceutical announced the approval of a new drug, indicating a significant development in its product portfolio [1] - The drug's marketing authorization has been transferred, which may enhance Fuyuan Pharmaceutical's market position and operational control [1]

Core Viewpoint - Fuyuan Pharmaceutical's subsidiary has received approval for the supplementary application of Salicylic Acid Phenol Plaster, enhancing the company's product line and market presence [1] Company Summary - Fuyuan Pharmaceutical's wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd., has been granted the "Drug Supplementary Application Approval Notice" for Salicylic Acid Phenol Plaster by the National Medical Products Administration [1] - The marketing authorization holder for this drug has been transferred from Xi'an Kanghua Pharmaceutical Co., Ltd. to Fuyuan Pharmaceutical Co., Ltd. [1] - The drug is primarily used for treating corns, and 16 other companies have also received marketing approvals for similar products [1] Market Summary - The estimated sales revenue for Salicylic Acid Phenol Plaster in China's three major terminal markets is approximately 68.92 million yuan in 2024 [1] - The approval allows Fuyuan Pharmaceutical to further diversify its product offerings, although future sales may be impacted by national policies and market conditions [1]